Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis
Open Access
- 29 May 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 1051
- https://doi.org/10.3389/fimmu.2020.01051
Abstract
Corticosteroids are effective therapy for autoimmune diseases but serious adverse effects preclude their prolonged use. However, immune-suppressive biologics that inhibit lymphoid proliferation are now in use as corticosteroid sparing-agents but with variable success; thus, the need to develop alternative immune-suppressive approaches including cell-based therapies. Efficacy of ex-vivo-generated IL-35-producing regulatory B-cells (i35-Bregs) in suppressing/ameliorating encephalomyelitis or uveitis in mouse models of multiple sclerosis or uveitis, respectively, is therefore a promising therapeutic approach for CNS autoimmune diseases. However, i35-Breg therapy in human uveitis would require producing autologous Bregs from each patient to avoid immune-rejection. Because exosomes exhibit minimal toxicity and immunogenicity, we investigated whether i35-Bregs release exosomes that can be exploited therapeutically. Here, we demonstrate that i35-Bregs release exosomes that contain IL-35 (i35-Exosomes). In this proof-of-concept study, we induced experimental autoimmune uveitis (EAU), monitored EAU progression by fundoscopy, histology, optical coherence tomography and electroretinography, and investigated whether i35-Exosomes treatment would suppress uveitis. Mice treated with i35-Exosomes developed mild EAU with low EAU scores and disease protection correlated with expansion of IL-10 and IL-35 secreting Treg cells with concomitant suppression of Th17 responses. In contrast, significant increase of Th17 cells in vitreous and retina of control mouse eyes was accompanied by severe choroiditis, massive retinal-folds, and photoreceptor cell damage. These hallmark features of severe uveitis were absent in exosome-treated mice and visual impairment detected by ERG was modest compared to control mice. Absence of toxicity or alloreactivity associated with exosomes thus makes i35-Exosomes attractive therapeutic option for delivering IL-35 into CNS tissues.Keywords
Funding Information
- National Eye Institute
This publication has 36 references indexed in Scilit:
- Activated Human T Cells Secrete Exosomes That Participate in IL-2 Mediated Immune Response SignalingPLOS ONE, 2012
- The adaptive immune system in diseases of the central nervous systemJCI Insight, 2012
- Autoreactive Memory CD4+ T Lymphocytes That Mediate Chronic Uveitis Reside in the Bone Marrow through STAT3-Dependent MechanismsPublished by The American Association of Immunologists ,2011
- Optic Nerve Crush Mice Followed Longitudinally with Spectral Domain Optical Coherence TomographyInvestigative Opthalmology & Visual Science, 2011
- Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector categoryThe Journal of Experimental Medicine, 2008
- Panretinal, High-Resolution Color Photography of the Mouse FundusPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2007
- TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1Nature Medicine, 2007
- Corrigendum to “Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration” [J. Autoimmun. 21 (2004) 283–293]Journal of Autoimmunity, 2004
- Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationJournal of Autoimmunity, 2003
- Pathology of experimental autoimmune uveoretinitis in miceJournal of Autoimmunity, 1990